Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.

Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, Deweese TL, Sgouros G.

Mol Cancer Ther. 2013 Oct;12(10):2043-54. doi: 10.1158/1535-7163.MCT-13-0108. Epub 2013 Jul 19.

2.

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.

Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, de Vries EG, van Tinteren H, Jonkers J, Hauptmann M, Rodenhuis S, Linn SC.

Breast Cancer Res. 2014 May 15;16(3):R47. doi: 10.1186/bcr3655.

3.

The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining.

Kriegs M, Kasten-Pisula U, Rieckmann T, Holst K, Saker J, Dahm-Daphi J, Dikomey E.

DNA Repair (Amst). 2010 Aug 5;9(8):889-97. doi: 10.1016/j.dnarep.2010.05.005. Epub 2010 Jun 19.

PMID:
20615764
4.

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.

Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA.

BMC Cancer. 2015 Mar 3;15:89. doi: 10.1186/s12885-015-1090-7.

5.

Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.

Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK.

Mol Cancer Ther. 2015 Apr;14(4):920-30. doi: 10.1158/1535-7163.MCT-14-0474.

6.

Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.

El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C.

Mol Carcinog. 2017 May;56(5):1383-1394. doi: 10.1002/mc.22596. Epub 2017 Mar 6.

PMID:
27864890
7.

mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.

Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y, Peng G, Meric-Bernstam F, Mills GB, Li K, Lin SY.

Clin Cancer Res. 2016 Apr 1;22(7):1699-712. doi: 10.1158/1078-0432.CCR-15-1772. Epub 2015 Nov 6.

8.

Suppression of DNA-dependent protein kinase sensitize cells to radiation without affecting DSB repair.

Gustafsson AS, Abramenkovs A, Stenerlöw B.

Mutat Res. 2014 Nov;769:1-10. doi: 10.1016/j.mrfmmm.2014.06.004. Epub 2014 Jun 22.

9.

The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.

Chen MC, Zhou B, Zhang K, Yuan YC, Un F, Hu S, Chou CM, Chen CH, Wu J, Wang Y, Liu X, Smith DL, Li H, Liu Z, Warden CD, Su L, Malkas LH, Chung YM, Hu MC, Yen Y.

Mol Pharmacol. 2015 Jun;87(6):996-1005. doi: 10.1124/mol.114.094987. Epub 2015 Mar 26.

10.

Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.

Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A.

PLoS One. 2015 Mar 16;10(3):e0119614. doi: 10.1371/journal.pone.0119614. eCollection 2015.

11.

Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.

Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J, Segerer SE.

Arch Gynecol Obstet. 2014 Jan;289(1):141-7. doi: 10.1007/s00404-013-2922-9. Epub 2013 Jul 5.

PMID:
23828443
12.

Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.

Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL.

Mol Cancer Ther. 2014 May;13(5):1356-68. doi: 10.1158/1535-7163.MCT-13-1021. Epub 2014 Mar 14.

13.

ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model.

Heravi M, Kumala S, Rachid Z, Jean-Claude BJ, Radzioch D, Muanza TM.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):399-406. doi: 10.1016/j.ijrobp.2015.01.026. Epub 2015 Mar 27.

PMID:
25823448
14.

Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.

Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF, Valerie K.

Cancer Biol Ther. 2009 Apr;8(8):730-8. Epub 2009 Apr 22.

15.

Relative biological effectiveness of high linear energy transfer α-particles for the induction of DNA-double-strand breaks, chromosome aberrations and reproductive cell death in SW-1573 lung tumour cells.

Franken NA, Hovingh S, Ten Cate R, Krawczyk P, Stap J, Hoebe R, Aten J, Barendsen GW.

Oncol Rep. 2012 Mar;27(3):769-74. doi: 10.3892/or.2011.1604. Epub 2011 Dec 21.

PMID:
22200791
16.

The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.

Lee Y, Li HK, Masaoka A, Sunada S, Hirakawa H, Fujimori A, Nickoloff JA, Okayasu R.

Radiother Oncol. 2016 Oct;121(1):162-168. doi: 10.1016/j.radonc.2016.08.029. Epub 2016 Sep 22.

17.

Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.

Kryeziu K, Jungwirth U, Hoda MA, Ferk F, Knasmüller S, Karnthaler-Benbakka C, Kowol CR, Berger W, Heffeter P.

Mol Cancer Ther. 2013 Jun;12(6):1073-84. doi: 10.1158/1535-7163.MCT-13-0065. Epub 2013 Apr 2.

18.

Therapeutic exploitation of tumor cell defects in homologous recombination.

Powell SN, Kachnic LA.

Anticancer Agents Med Chem. 2008 May;8(4):448-60. Review.

PMID:
18473729
19.

The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.

Xia Q, Cai Y, Peng R, Wu G, Shi Y, Jiang W.

Int J Oncol. 2014 Mar;44(3):735-44. doi: 10.3892/ijo.2013.2240. Epub 2013 Dec 31.

PMID:
24378347
20.

Comparison of RBE values of high-LET α-particles for the induction of DNA-DSBs, chromosome aberrations and cell reproductive death.

Franken NA, ten Cate R, Krawczyk PM, Stap J, Haveman J, Aten J, Barendsen GW.

Radiat Oncol. 2011 Jun 8;6:64. doi: 10.1186/1748-717X-6-64.

Supplemental Content

Support Center